SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)
$19.84 0.55 (2.8512%)
Analysed SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) News Sources
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
14-07-2026
yahoo.com
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
14-07-2026
marketbeat.com
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
28-07-2026
yahoo.com
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
04-08-2026
yahoo.com
Syndax Pharmaceuticals Q2 Earnings Call Highlights
05-08-2026
marketbeat.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05-08-2026
yahoo.com
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
07-08-2026
yahoo.com
Syndax (SNDX) Q2 2026 Earnings Call Transcript
12-08-2026
fool.com
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
12-08-2026
yahoo.com
Syndax Announces Participation in September Investor Conferences
01-09-2026
yahoo.com
What is the current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is $19.84.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is $0.55.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is 2.8512%.
What is the most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is .
SEC-8K** Filing Available For SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.